Clinical Trial Update: A Phase 2 Trial of Glofitamab for Minimal Residual Disease in Patients With Large B-cell Lymphoma [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating glofitamab for minimal residual disease in patients with diffuse large B-cell lymphoma has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diffuse Large B-cell Lymphoma

Drugs mentioned

• Glofitamab (glofitamab)

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: B-cell Lymphoma | Phase 2 | Status: WITHDRAWN